Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: Irinotecan
Drug: Oxaliplatin
Drug: Trastuzumab
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2013-08-23

Last Posted Date: 2020-08-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 67

Registration Number: NCT01928290

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Regorafenib
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2013-08-01

Last Posted Date: 2020-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01913639

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: 5-FU
Drug: Carboplatin
Drug: Cisplatin
Drug: MEHD7945A
Drug: Paclitaxel

First Posted Date: 2013-07-30

Last Posted Date: 2017-07-06

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT01911598

Locations: 🇺🇸
University of Chicago; Hematology/Oncology, Chicago, Illinois, United States
🇺🇸
University of Colorado Cancer Center Department of Hematology, Aurora, Colorado, United States
🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium

and more 3 locations

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Phase 2

Terminated

Conditions: Stage IIA Pancreatic Cancer
Stage IIB Pancreatic Cancer
Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer

Interventions: Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Radiation: Intensity-Modulated Radiation Therapy
Drug: Irinotecan Hydrochloride
Drug: Leucovorin Calcium
Drug: Oxaliplatin

First Posted Date: 2013-07-12

Last Posted Date: 2023-12-05

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 23

Registration Number: NCT01897454

Locations: 🇺🇸
Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Ipatasertib
Drug: Leucovorin
Drug: Placebo
Drug: Oxaliplatin

First Posted Date: 2013-07-11

Last Posted Date: 2022-03-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 153

Registration Number: NCT01896531

Locations: 🇺🇸
Univ of Calif, Los Angeles; Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States
🇮🇹
Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica, Pisa, Toscana, Italy

and more 31 locations

Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Duct Cell Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: fluorouracil
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2013-07-09

Last Posted Date: 2017-03-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 1

Registration Number: NCT01893294

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer
Metastatic Colorectal Cancer

Interventions: Drug: 5-FU
Drug: LV
Drug: ziv-aflibercept
Drug: mFOLFOX6

First Posted Date: 2013-06-28

Last Posted Date: 2014-12-02

Lead Sponsor: NSABP Foundation Inc

Registration Number: NCT01889680

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Hypopharynx Stage IV
Squamous Cell Carcinoma of the Oropharynx Stage III
Squamous Cell Carcinoma of the Larynx Stage III
Squamous Cell Carcinoma of the Oral Cavity Stage IV
Squamous Cell Carcinoma of the Hypopharynx Stage III
Squamous Cell Carcinoma of the Larynx Stage IV
Squamous Cell Carcinoma of the Oropharynx Stage IV
Squamous Cell Carcinoma of the Oral Cavity Stage III

Interventions: Drug: Docetaxel
Drug: Cisplatin
Biological: Cetuximab Induction
Drug: 5-fluorouracil
Biological: Cetuximab Radioimmunotherapy
Radiation: Boost irradiation

First Posted Date: 2013-06-24

Last Posted Date: 2022-05-26

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 100

Registration Number: NCT01884259

Locations: 🇦🇹
Hanusch Krankenhaus Wien, Vienna, Austria
🇦🇹
Universität f. Strahlentherape, AKH Wien, Vienna, Austria
🇦🇹
Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Austria

and more 5 locations

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Phase 2

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Aflibercept
Drug: Levofolinate
Drug: Irinotecan
Drug: 5-FU

First Posted Date: 2013-06-20

Last Posted Date: 2017-03-14

Lead Sponsor: Sanofi

Target Recruit Count: 62

Registration Number: NCT01882868

Locations: 🇯🇵
Investigational Site Number 392002, Sunto-Gun, Japan
🇯🇵
Investigational Site Number 392005, Suita-Shi, Japan
🇯🇵
Investigational Site Number 392017, Fukuoka-Shi, Japan

and more 16 locations

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Phase 1

Conditions: Inflammatory Breast Cancer

Interventions: Biological: Bevacizumab
Drug: Cyclophosphamide
Drug: epirubicin hydrochloride
Drug: fluorouracil
Drug: Docetaxel
Biological: Trastuzumab

First Posted Date: 2013-06-19

Last Posted Date: 2013-06-19

Lead Sponsor: Association Tunisienne de lutte Contre le Cancer

Target Recruit Count: 30

Registration Number: NCT01880385

Locations: 🇹🇳
Institut Salah Azaiz, Bab Saadoun, Tunis, Tunisia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy